Verastem, Inc. stock is up 5.31% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 11 November’s closed higher than October. 100% of analysts rate it a buy.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.